The a2 Milk Company has received approval from China’s State Administration for Market Regulation (SAMR) to transition two infant milk formula product registrations acquired through its a2 Pokeno facility into a2 branded products. This regulatory clearance represents the final step required to complete the company’s acquisition of the Pokeno facility, removing the last material hurdle standing between a2MC and full realization of the deal’s intended benefits.
The significance of this approval extends beyond the purely administrative. With SAMR approval now secured, the company has lost its contractual right to unwind the Pokeno acquisition, transforming the deal from conditional to irreversible. Product launches are expected later in 2026, with no changes to the timeline or financial benefits previously communicated when the acquisition was announced. This certainty removes a material uncertainty that investors have carried since the acquisition was first disclosed, and it signals management confidence that integration remains on track.
The financial upside for shareholders appears substantial. The company has indicated that the board intends to declare a $300 million special dividend, fully franked and unimputed, following receipt of these regulatory approvals. This represents a material return of capital to shareholders, reflecting the company’s view that the transaction value has been captured and can now be distributed. Dividend timing and payment details will be announced separately, but the signal is clear that shareholders will benefit directly from the Pokeno facility acquisition.
From a strategic perspective, SAMR approval validates a key part of a2MC’s medium-term growth model. China remains the company’s primary market, and the Pokeno acquisition promised dual benefits: established market access through registered products and the ability to build advanced infant formula manufacturing capability within China itself. The approval enables rebranding these products as a2 branded offerings, a crucial step because the a2 brand commands premium positioning and pricing power in China’s infant formula market. This combination of supply chain control, manufacturing capability, and market access should support both volume growth and margin expansion in the company’s largest market.
Investors should watch for several indicators of whether the acquisition delivers promised value. First, the financial performance of the new a2 branded products following their launch later in 2026 will signal whether revenue and margin benefits are tracking as expected. Second, timing of the special dividend declaration and payment will affect shareholder returns in the near term. Third, competitive responses from other infant formula players in China may shift the attractiveness of the acquired registrations. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About The a2 Milk Company Limited (ASX: A2M)
The a2 Milk Company Limited is a dairy nutritionals company that sells A2-type protein branded milk and related products, including infant milk formula and other dairy products. The company operates across Australia, New Zealand, China, rest of Asia, and the United States, manufacturing and selling nutritional products and providing licensing services under the a2 Milk and a2 Platinum brands.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
